2015
Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.
Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. Journal Of The National Comprehensive Cancer Network 2015, 13: e1-7. PMID: 25583775, DOI: 10.6004/jnccn.2015.0014.Peer-Reviewed Original ResearchConceptsFebrile neutropeniaHigh riskNCCN Clinical Practice GuidelinesBroad-spectrum antibiotic treatmentCommon dose-limiting toxicityChemotherapy dose reductionsConsideration of prophylaxisLow-risk regimensDose-limiting toxicityChemotherapy-induced neutropeniaClinical practice guidelinesHealth care useEpisode of careMyeloid growth factorsGrowth factor useEarly treatment terminationHealth care costsPrimary prophylaxisMyelosuppressive chemotherapySupportive careSerious morbidityTreatment delayTherapeutic optionsAntibiotic treatmentCare use
2010
Commentary: Personalized Health Planning and the Patient Protection and Affordable Care Act: An Opportunity for Academic Medicine to Lead Health Care Reform
Dinan MA, Simmons LA, Snyderman R. Commentary: Personalized Health Planning and the Patient Protection and Affordable Care Act: An Opportunity for Academic Medicine to Lead Health Care Reform. Academic Medicine 2010, 85: 1665-1668. PMID: 20844424, DOI: 10.1097/acm.0b013e3181f4ab3c.Peer-Reviewed Original ResearchConceptsPersonalized health planningHealth planningAffordable Care ActCare deliveryHealth care reformPatient-centered medical homeCoordinated care approachPersonalized health plansPatient ProtectionCare ActDisease management programsPatient's specific needsHealth care deliveryStrategic health planningCare reformCore clinical processesBroad clinical applicationAccountable care organizationsCoordinated careHealth centersMedical homeValue-based reimbursementCare approachAcademic health centersTrue health care reform